{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T06:04:30Z","timestamp":1792735470114,"version":"4.5.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T00:00:00Z","timestamp":1600387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T00:00:00Z","timestamp":1600387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["H29-022"],"award-info":[{"award-number":["H29-022"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"The Ministry of Education, Culture, Sports, Science and Technology of Japan","doi-asserted-by":"crossref","award":["17K09777"],"award-info":[{"award-number":["17K09777"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s40120-020-00210-7","type":"journal-article","created":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T16:03:32Z","timestamp":1600445012000},"page":"317-333","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":106,"title":["Transthyretin Amyloidosis: Update on the Clinical Spectrum, Pathogenesis, and Disease-Modifying Therapies"],"prefix":"10.1007","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4612-3183","authenticated-orcid":false,"given":"Haruki","family":"Koike","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahisa","family":"Katsuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,18]]},"reference":[{"key":"210_CR1","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41582-019-0210-4","volume":"15","author":"D Adams","year":"2019","unstructured":"Adams D, Koike H, Slama M, Coelho T. Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. Nat Rev Neurol. 2019;15:387\u2013404.","journal-title":"Nat Rev Neurol"},{"key":"210_CR2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3390\/biomedicines7010011","volume":"7","author":"H Koike","year":"2019","unstructured":"Koike H, Katsuno M. Ultrastructure in transthyretin amyloidosis: from pathophysiology to therapeutic insights. Biomedicines. 2019;7:11.","journal-title":"Biomedicines"},{"key":"210_CR3","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/13506129.2018.1549825","volume":"25","author":"MD Benson","year":"2018","unstructured":"Benson MD, Buxbaum JN, Eisenberg DS, et al. Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee. Amyloid. 2018;25:215\u20139.","journal-title":"Amyloid"},{"key":"210_CR4","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1097\/00007890-199806150-00016","volume":"65","author":"AJ Stangou","year":"1998","unstructured":"Stangou AJ, Heaton ND, Rela M, Pepys MB, Hawkins PN, Williams R. Domino hepatic transplantation using the liver from a patient with familial amyloid polyneuropathy. Transplantation. 1998;65:1496\u20138.","journal-title":"Transplantation"},{"key":"210_CR5","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3109\/13506129.2011.565524","volume":"18","author":"H Koike","year":"2011","unstructured":"Koike H, Hashimoto R, Tomita M, et al. Diagnosis of sporadic transthyretin Val30Met familial amyloid polyneuropathy: a practical analysis. Amyloid. 2011;18:53\u201362.","journal-title":"Amyloid"},{"key":"210_CR6","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/0002-9343(83)90443-6","volume":"75","author":"GG Cornwell 3rd","year":"1983","unstructured":"Cornwell GG 3rd, Murdoch WL, Kyle RA, Westermark P, Pitk\u00e4nen P. Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation. Am J Med. 1983;75:618\u201323.","journal-title":"Am J Med"},{"key":"210_CR7","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/modpathol.2011.117","volume":"24","author":"M Ueda","year":"2011","unstructured":"Ueda M, Horibata Y, Shono M, et al. Clinicopathological features of senile systemic amyloidosis: an ante- and post-mortem study. Mod Pathol. 2011;24:1533\u201344.","journal-title":"Mod Pathol"},{"key":"210_CR8","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","volume":"36","author":"E Gonz\u00e1lez-L\u00f3pez","year":"2015","unstructured":"Gonz\u00e1lez-L\u00f3pez E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36:2585\u201394.","journal-title":"Eur Heart J"},{"key":"210_CR9","doi-asserted-by":"publisher","unstructured":"Griffin JM, Maurer MS. Transthyretin cardiac amyloidosis: a treatable form of heart failure with a preserved ejection fraction. Trends Cardiovasc Med. https:\/\/doi.org\/10.1016\/j.tcm.2019.12.003.","DOI":"10.1016\/j.tcm.2019.12.003"},{"key":"210_CR10","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1080\/13506129.2017.1409706","volume":"25","author":"Y Sekijima","year":"2018","unstructured":"Sekijima Y, Yazaki M, Ueda M, Koike H, Yamada M, Ando Y. First nationwide survey on systemic wild-type ATTR amyloidosis in Japan. Amyloid. 2018;25:8\u201310.","journal-title":"Amyloid"},{"key":"210_CR11","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.humpath.2011.03.004","volume":"42","author":"Y Sekijima","year":"2011","unstructured":"Sekijima Y, Uchiyama S, Tojo K, et al. High prevalence of wild-type transthyretin deposition in patients with idiopathic carpal tunnel syndrome: a common cause of carpal tunnel syndrome in the elderly. Hum Pathol. 2011;42:1785\u201391.","journal-title":"Hum Pathol"},{"key":"210_CR12","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3109\/03009734.2014.895786","volume":"119","author":"P Westermark","year":"2014","unstructured":"Westermark P, Westermark GT, Suhr OB, Berg S. Transthyretin-derived amyloidosis: probably a common cause of lumbar spinal stenosis. Ups J Med Sci. 2014;119:223\u20138.","journal-title":"Ups J Med Sci"},{"key":"210_CR13","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/modpathol.2014.102","volume":"28","author":"A Yanagisawa","year":"2015","unstructured":"Yanagisawa A, Ueda M, Sueyoshi T, et al. Amyloid deposits derived from transthyretin in the ligamentum flavum as related to lumbar spinal canal stenosis. Mod Pathol. 2015;28:201\u20137.","journal-title":"Mod Pathol"},{"key":"210_CR14","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.15252\/emmm.201505357","volume":"7","author":"J Marcoux","year":"2015","unstructured":"Marcoux J, Mangione PP, Porcari R, et al. A novel mechano-enzymatic cleavage mechanism underlies transthyretin amyloidogenesis. EMBO Mol Med. 2015;7:1337\u201349.","journal-title":"EMBO Mol Med"},{"key":"210_CR15","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/mus.26723","volume":"61","author":"MV Pinto","year":"2020","unstructured":"Pinto MV, Milone M, Mauermann ML, et al. Transthyretin amyloidosis: putting myopathy on the map. Muscle Nerve. 2020;61:95\u2013100.","journal-title":"Muscle Nerve"},{"key":"210_CR16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/mus.26741","volume":"61","author":"H Koike","year":"2020","unstructured":"Koike H, Katsuno M. Expanding the spectrum of transthyretin amyloidosis. Muscle Nerve. 2020;61:3\u20134.","journal-title":"Muscle Nerve"},{"key":"210_CR17","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1001\/archneur.59.11.1771","volume":"59","author":"H Koike","year":"2002","unstructured":"Koike H, Misu K, Ikeda S, et al. Type I (transthyretin Met30) familial amyloid polyneuropathy in Japan: early- vs late-onset form. Arch Neurol. 2002;59:1771\u20136.","journal-title":"Arch Neurol"},{"key":"210_CR18","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13023-017-0726-x","volume":"13","author":"Y Sekijima","year":"2018","unstructured":"Sekijima Y, Ueda M, Koike H, Misawa S, Ishii T, Ando Y. Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm. Orphanet J Rare Dis. 2018;13:6.","journal-title":"Orphanet J Rare Dis"},{"key":"210_CR19","first-page":"1","volume":"590","author":"R Andersson","year":"1976","unstructured":"Andersson R. Familial amyloidosis with polyneuropathy. A clinical study based on patients living in Northern Sweden. Acta Med Scand Suppl. 1976;590:1\u201364.","journal-title":"Acta Med Scand Suppl"},{"key":"210_CR20","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1007\/s00415-008-0962-z","volume":"255","author":"H Koike","year":"2008","unstructured":"Koike H, Kawagashira Y, Iijima M, et al. Electrophysiological features of late-onset transthyretin Met30 familial amyloid polyneuropathy unrelated to endemic foci. J Neurol. 2008;255:1526\u201333.","journal-title":"J Neurol"},{"key":"210_CR21","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1212\/01.WNL.0000132966.36437.12","volume":"63","author":"H Koike","year":"2004","unstructured":"Koike H, Misu K, Sugiura M, et al. Pathology of early- vs late-onset TTR Met30 familial amyloid polyneuropathy. Neurology. 2004;63:129\u201338.","journal-title":"Neurology"},{"key":"210_CR22","doi-asserted-by":"crossref","first-page":"e1999","DOI":"10.1212\/WNL.0000000000006543","volume":"91","author":"T Coelho","year":"2018","unstructured":"Coelho T, In\u00eas M, Concei\u00e7\u00e3o I, Soares M, de Carvalho M, Costa J. Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathy. Neurology. 2018;91:e1999\u20132009.","journal-title":"Neurology"},{"key":"210_CR23","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1136\/jnnp-2011-301299","volume":"83","author":"H Koike","year":"2012","unstructured":"Koike H, Tanaka F, Hashimoto R, et al. Natural history of transthyretin Val30Met familial amyloid polyneuropathy: analysis of late-onset cases from non-endemic areas. J Neurol Neurosurg Psychiatry. 2012;83:152\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"210_CR24","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/ncn3.12306","volume":"7","author":"H Koike","year":"2019","unstructured":"Koike H, Fukami Y, Nishi R, et al. Clinicopathological spectrum and recent advances in the treatment of hereditary transthyretin amyloidosis. Neurol Clin Neurosci. 2019;7:166\u201373.","journal-title":"Neurol Clin Neurosci"},{"key":"210_CR25","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/jns.12381","volume":"25","author":"L Obici","year":"2020","unstructured":"Obici L, Adams D. Acquired and inherited amyloidosis: knowledge driving patients' care. J Peripher Nerv Syst. 2020;25:85\u2013101.","journal-title":"J Peripher Nerv Syst"},{"key":"210_CR26","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.2169\/internalmedicine.1113-18","volume":"57","author":"H Koike","year":"2018","unstructured":"Koike H, Nakamura T, Nishi R, et al. Widespread cardiac and vasomotor autonomic dysfunction in non-Val30Met hereditary transthyretin amyloidosis. Intern Med. 2018;57:3365\u201370.","journal-title":"Intern Med"},{"key":"210_CR27","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/gim.2016.200","volume":"19","author":"JN Buxbaum","year":"2017","unstructured":"Buxbaum JN, Ruberg FL. Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans. Genet Med. 2017;19:733\u201342.","journal-title":"Genet Med"},{"key":"210_CR28","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2019.17935","volume":"322","author":"SM Damrauer","year":"2019","unstructured":"Damrauer SM, Chaudhary K, Cho JH, et al. Association of the V122I hereditary transthyretin amyloidosis genetic variant with heart failure among individuals of African or Hispanic\/Latino ancestry. JAMA. 2019;322:2191\u2013202.","journal-title":"JAMA"},{"key":"210_CR29","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1001\/archneur.56.9.1152","volume":"56","author":"T Uemichi","year":"1999","unstructured":"Uemichi T, Uitti RJ, Koeppen AH, Donat JR, Benson MD. Oculoleptomeningeal amyloidosis associated with a new transthyretin variant Ser64. Arch Neurol. 1999;56:1152\u20135.","journal-title":"Arch Neurol"},{"key":"210_CR30","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1399-0004.1991.tb03085.x","volume":"40","author":"G Holmgren","year":"1991","unstructured":"Holmgren G, Steen L, Ekstedt J, et al. Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). Clin Genet. 1991;40:242\u20136.","journal-title":"Clin Genet"},{"key":"210_CR31","doi-asserted-by":"crossref","first-page":"e1587","DOI":"10.1212\/WNL.0000000000008360","volume":"93","author":"Y Misumi","year":"2019","unstructured":"Misumi Y, Ueda M, Masuda T, et al. Characteristics of acquired transthyretin amyloidosis: a case series and review of the literature. Neurology. 2019;93:e1587\u2013e15961596.","journal-title":"Neurology"},{"key":"210_CR32","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1056\/NEJM200506023522219","volume":"352","author":"AJ Stangou","year":"2005","unstructured":"Stangou AJ, Heaton ND, Hawkins PN. Transmission of systemic transthyretin amyloidosis by means of domino liver transplantation. N Engl J Med. 2005;352:2356.","journal-title":"N Engl J Med"},{"key":"210_CR33","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1111\/j.1600-6143.2006.01484.x","volume":"6","author":"T Goto","year":"2006","unstructured":"Goto T, Yamashita T, Ueda M, et al. Iatrogenic amyloid neuropathy in a Japanese patient after sequential liver transplantation. Am J Transplant. 2006;6:2512\u20135.","journal-title":"Am J Transplant"},{"key":"210_CR34","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/lt.21928","volume":"16","author":"AP Barreiros","year":"2010","unstructured":"Barreiros AP, Geber C, Birklein F, Galle PR, Otto G. Clinical symptomatic de novo systemic transthyretin amyloidosis 9 years after domino liver transplantation. Liver Transpl. 2010;16:109.","journal-title":"Liver Transpl"},{"key":"210_CR35","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1136\/jnnp.2010.218958","volume":"82","author":"H Koike","year":"2011","unstructured":"Koike H, Kiuchi T, Iijima M, et al. Systemic but asymptomatic transthyretin amyloidosis 8 years after domino liver transplantation. J Neurol Neurosurg Psychiatry. 2011;82:1287\u201390.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"210_CR36","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/jnnp-2013-306241","volume":"85","author":"H Koike","year":"2014","unstructured":"Koike H, Sobue G. What is the prototype of familial amyloid polyneuropathy? J Neurol Neurosurg Psychiatry. 2014;85:713.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"210_CR37","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0969-2126(97)00215-3","volume":"5","author":"JW Kelly","year":"1997","unstructured":"Kelly JW. Amyloid fibril formation and protein misassembly: a structural quest for insights into amyloid and prion diseases. Structure. 1997;5:595\u2013600.","journal-title":"Structure"},{"key":"210_CR38","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cell.2005.01.018","volume":"121","author":"Y Sekijima","year":"2005","unstructured":"Sekijima Y, Wiseman RL, Matteson J, et al. The biological and chemical basis for tissue-selective amyloid disease. Cell. 2005;121:73\u201385.","journal-title":"Cell"},{"key":"210_CR39","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1073\/pnas.87.7.2843","volume":"87","author":"P Westermark","year":"1990","unstructured":"Westermark P, Sletten K, Johansson B, Cornwell GG 3rd. Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci USA. 1990;87:2843\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"210_CR40","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jns.2009.07.028","volume":"287","author":"H Koike","year":"2009","unstructured":"Koike H, Ando Y, Ueda M, et al. Distinct characteristics of amyloid deposits in early- and late-onset transthyretin Val30Met familial amyloid polyneuropathy. J Neurol Sci. 2009;287:178\u201384.","journal-title":"J Neurol Sci"},{"key":"210_CR41","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1600-6143.2006.01585.x","volume":"7","author":"M Yazaki","year":"2007","unstructured":"Yazaki M, Mitsuhashi S, Tokuda T, et al. Progressive wild-type transthyretin deposition after liver transplantation preferentially occurs onto myocardium in FAP patients. Am J Transplant. 2007;7:235\u201342.","journal-title":"Am J Transplant"},{"key":"210_CR42","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1002\/lt.21817","volume":"15","author":"S Okamoto","year":"2009","unstructured":"Okamoto S, Wixner J, Obayashi K, et al. Liver transplantation for familial amyloidotic polyneuropathy: impact on Swedish patients' survival. Liver Transpl. 2009;15:1229\u2013355.","journal-title":"Liver Transpl"},{"key":"210_CR43","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/path.1759","volume":"206","author":"J Bergstr\u00f6m","year":"2005","unstructured":"Bergstr\u00f6m J, Gustavsson A, Hellman U, et al. Amyloid deposits in transthyretin-derived amyloidosis: cleaved transthyretin is associated with distinct amyloid morphology. J Pathol. 2005;206:224\u201332.","journal-title":"J Pathol"},{"key":"210_CR44","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/joim.12585","volume":"281","author":"OB Suhr","year":"2017","unstructured":"Suhr OB, Lundgren E, Westermark P. One mutation, two distinct disease variants: unravelling the impact of transthyretin amyloid fibril composition. J Intern Med. 2017;281:337\u201347.","journal-title":"J Intern Med"},{"key":"210_CR45","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1021\/acs.biochem.0c00079","volume":"59","author":"AKR Dasari","year":"2020","unstructured":"Dasari AKR, Arreola J, Michael B, Griffin RG, Kelly JW, Lim KH. Disruption of the CD loop by enzymatic cleavage promotes the formation of toxic transthyretin oligomers through a common transthyretin misfolding pathway. Biochemistry. 2020;59:2319\u201327.","journal-title":"Biochemistry"},{"key":"210_CR46","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jns.2018.09.011","volume":"394","author":"H Koike","year":"2018","unstructured":"Koike H, Nishi R, Ikeda S, et al. The morphology of amyloid fibrils and their impact on tissue damage in hereditary transthyretin amyloidosis: an ultrastructural study. J Neurol Sci. 2018;394:99\u2013106.","journal-title":"J Neurol Sci"},{"key":"210_CR47","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/S0002-9440(10)63050-7","volume":"159","author":"MM Sousa","year":"2001","unstructured":"Sousa MM, Cardoso I, Fernandes R, Guimar\u00e3es A, Saraiva MJ. Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. Am J Pathol. 2001;159:1993\u20132000.","journal-title":"Am J Pathol"},{"key":"210_CR48","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/S0002-9440(10)64469-0","volume":"161","author":"MM Sousa","year":"2002","unstructured":"Sousa MM, Fernandes R, Palha JA, Taboada A, Vieira P, Saraiva MJ. Evidence for early cytotoxic aggregates in transgenic mice for human transthyretin Leu55Pro. Am J Pathol. 2002;161:1935\u201348.","journal-title":"Am J Pathol"},{"key":"210_CR49","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.bbrc.2006.11.045","volume":"352","author":"M Ueda","year":"2007","unstructured":"Ueda M, Ando Y, Hakamata Y, et al. A transgenic rat with the human ATTR V30M: a novel tool for analyses of ATTR metabolisms. Biochem Biophys Res Commun. 2007;352:299\u2013304.","journal-title":"Biochem Biophys Res Commun"},{"key":"210_CR50","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/path.2618","volume":"219","author":"Y Misumi","year":"2009","unstructured":"Misumi Y, Ando Y, Ueda M, et al. Chain reaction of amyloid fibril formation with induction of basement membrane in familial amyloidotic polyneuropathy. J Pathol. 2009;219:481\u201390.","journal-title":"J Pathol"},{"key":"210_CR51","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1212\/WNL.0000000000003362","volume":"87","author":"H Koike","year":"2016","unstructured":"Koike H, Ikeda S, Takahashi M, et al. Schwann cell and endothelial cell damage in transthyretin familial amyloid polyneuropathy. Neurology. 2016;87:2220\u20139.","journal-title":"Neurology"},{"key":"210_CR52","first-page":"295","volume":"54","author":"H Koike","year":"2017","unstructured":"Koike H. Pathology of familial amyloid polyneuropathy. Jiritushinkei. 2017;54:295\u2013305.","journal-title":"Jiritushinkei"},{"key":"210_CR53","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/ana.410370412","volume":"37","author":"C Giannini","year":"1995","unstructured":"Giannini C, Dyck PJ. Basement membrane reduplication and pericyte degeneration precede development of diabetic polyneuropathy and are associated with its severity. Ann Neurol. 1995;37:498\u2013504.","journal-title":"Ann Neurol"},{"key":"210_CR54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vph.2017.01.004","volume":"90","author":"R Madonna","year":"2017","unstructured":"Madonna R, Balistreri CR, Geng YJ, De Caterina R. Diabetic microangiopathy: pathogenetic insights and novel therapeutic approaches. Vasc Pharmacol. 2017;90:1\u20137.","journal-title":"Vasc Pharmacol"},{"key":"210_CR55","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1046\/j.1365-2796.2000.00668.x","volume":"247","author":"N Nyhlin","year":"2000","unstructured":"Nyhlin N, Ando Y, Nagai R, et al. Advanced glycation end product in familial amyloidotic polyneuropathy (FAP). J Intern Med. 2000;247:485\u201392.","journal-title":"J Intern Med"},{"key":"210_CR56","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41598-018-37230-1","volume":"9","author":"AKR Dasari","year":"2019","unstructured":"Dasari AKR, Hughes RM, Wi S, et al. Transthyretin aggregation pathway toward the formation of distinct cytotoxic oligomers. Sci Rep. 2019;9:33.","journal-title":"Sci Rep"},{"key":"210_CR57","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1471-4159.2006.03716.x","volume":"97","author":"FA Monteiro","year":"2006","unstructured":"Monteiro FA, Sousa MM, Cardoso I, do Amaral JB, Guimar\u00e3es A, Saraiva MJ. Activation of ERK1\/2 MAP kinases in familial amyloidotic polyneuropathy. J Neurochem. 2006;97:151\u201361.","journal-title":"J Neurochem"},{"key":"210_CR58","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.neuro.2013.08.013","volume":"39","author":"VH Fong","year":"2013","unstructured":"Fong VH, Vieira A. Pro-oxidative effects of aggregated transthyretin in human Schwannoma cells. Neurotoxicology. 2013;39:109\u201313.","journal-title":"Neurotoxicology"},{"key":"210_CR59","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s00018-019-03357-1","volume":"77","author":"RB Ibrahim","year":"2020","unstructured":"Ibrahim RB, Yeh SY, Lin KP, et al. Cellular secretion and cytotoxicity of transthyretin mutant proteins underlie late-onset amyloidosis and neurodegeneration. Cell Mol Life Sci. 2020;77:1421\u201334.","journal-title":"Cell Mol Life Sci"},{"key":"210_CR60","doi-asserted-by":"crossref","first-page":"E7710","DOI":"10.1073\/pnas.1801117115","volume":"115","author":"K Madhivanan","year":"2018","unstructured":"Madhivanan K, Greiner ER, Alves-Ferreira M, et al. Cellular clearance of circulating transthyretin decreases cell-nonautonomous proteotoxicity in Caenorhabditis elegans. Proc Natl Acad Sci USA. 2018;115:E7710\u2013E7719719.","journal-title":"Proc Natl Acad Sci USA"},{"key":"210_CR61","doi-asserted-by":"crossref","first-page":"31752","DOI":"10.1074\/jbc.M113.469858","volume":"288","author":"RJ Nunes","year":"2013","unstructured":"Nunes RJ, de Oliveira P, Lages A, et al. Transthyretin proteins regulate angiogenesis by conferring different molecular identities to endothelial cells. J Biol Chem. 2013;288:31752\u201360.","journal-title":"J Biol Chem"},{"key":"210_CR62","doi-asserted-by":"crossref","first-page":"991","DOI":"10.4049\/jimmunol.1800736","volume":"202","author":"CC Lee","year":"2019","unstructured":"Lee CC, Ding X, Zhao T, et al. Transthyretin stimulates tumor growth through regulation of tumor immune, and endothelial cells. J Immunol. 2019;202:991\u20131002.","journal-title":"J Immunol"},{"key":"210_CR63","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1159\/000481562","volume":"43","author":"J Shao","year":"2017","unstructured":"Shao J, Yin Y, Yin X, et al. Transthyretin exerts pro-apoptotic effects in human retinal microvascular endothelial cells through a grp78-dependent pathway in diabetic retinopathy. Cell Physiol Biochem. 2017;43:788\u2013800.","journal-title":"Cell Physiol Biochem"},{"key":"210_CR64","doi-asserted-by":"crossref","first-page":"6313","DOI":"10.3390\/ijms20246313","volume":"20","author":"G Fan","year":"2019","unstructured":"Fan G, Gu Y, Zhang J, et al. Transthyretin upregulates long non-coding RNA MEG3 by affecting PABPC1 in diabetic retinopathy. Int J Mol Sci. 2019;20:6313.","journal-title":"Int J Mol Sci"},{"key":"210_CR65","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1212\/WNL.0000000000004178","volume":"89","author":"J Kollmer","year":"2017","unstructured":"Kollmer J, Sahm F, Hegenbart U, et al. Sural nerve injury in familial amyloid polyneuropathy: MR neurography vs clinicopathologic tools. Neurology. 2017;89:475\u201384.","journal-title":"Neurology"},{"key":"210_CR66","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jacc.2017.05.053","volume":"70","author":"A Martinez-Naharro","year":"2017","unstructured":"Martinez-Naharro A, Treibel TA, Abdel-Gadir A, et al. Magnetic resonance in transthyretin cardiac amyloidosis. J Am Coll Cardiol. 2017;70:466\u201377.","journal-title":"J Am Coll Cardiol"},{"key":"210_CR67","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1212\/WNL.0b013e318248df18","volume":"78","author":"T Yamashita","year":"2012","unstructured":"Yamashita T, Ando Y, Okamoto S, et al. Long-term survival after liver transplantation in patients with familial amyloid polyneuropathy. Neurology. 2012;78:637\u201343.","journal-title":"Neurology"},{"key":"210_CR68","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/TP.0000000000000574","volume":"99","author":"BG Ericzon","year":"2015","unstructured":"Ericzon BG, Wilczek HE, Larsson M, et al. Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative? Transplantation. 2015;99:1847\u201354.","journal-title":"Transplantation"},{"key":"210_CR69","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1212\/WNL.0b013e3181ea15d4","volume":"75","author":"JJ Liepnieks","year":"2010","unstructured":"Liepnieks JJ, Zhang LQ, Benson MD. Progression of transthyretin amyloid neuropathy after liver transplantation. Neurology. 2010;75:324\u20137.","journal-title":"Neurology"},{"key":"210_CR70","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/mus.23480","volume":"46","author":"H Koike","year":"2012","unstructured":"Koike H, Hashimoto R, Tomita M, et al. Impact of aging on the progression of neuropathy after liver transplantation in transthyretin Val30Met amyloidosis. Muscle Nerve. 2012;46:964\u201370.","journal-title":"Muscle Nerve"},{"key":"210_CR71","doi-asserted-by":"crossref","first-page":"12956","DOI":"10.1073\/pnas.95.22.12956","volume":"95","author":"SA Peterson","year":"1998","unstructured":"Peterson SA, Klabunde T, Lashuel HA, Purkey H, Sacchettini JC, Kelly JW. Inhibiting transthyretin conformational changes that lead to amyloid fibril formation. Proc Natl Acad Sci USA. 1998;95:12956\u201360.","journal-title":"Proc Natl Acad Sci USA"},{"key":"210_CR72","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/labinvest.3700059","volume":"84","author":"SR Miller","year":"2004","unstructured":"Miller SR, Sekijima Y, Kelly JW. Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. Lab Investig. 2004;84:545\u201352.","journal-title":"Lab Investig"},{"key":"210_CR73","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","volume":"79","author":"T Coelho","year":"2012","unstructured":"Coelho T, Maia LF, da Silva AM, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79:785\u201392.","journal-title":"Neurology"},{"key":"210_CR74","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1001\/jama.2013.283815","volume":"310","author":"JL Berk","year":"2013","unstructured":"Berk JL, Suhr OB, Obici L, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013;310:2658\u201367.","journal-title":"JAMA"},{"key":"210_CR75","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379:1007\u2013166.","journal-title":"N Engl J Med"},{"key":"210_CR76","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1080\/13506129.2017.1357545","volume":"24","author":"FA Barroso","year":"2017","unstructured":"Barroso FA, Judge DP, Ebede B, et al. Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years. Amyloid. 2017;24:194\u2013204.","journal-title":"Amyloid"},{"key":"210_CR77","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:11\u201321.","journal-title":"N Engl J Med"},{"key":"210_CR78","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:22\u201331.","journal-title":"N Engl J Med"},{"key":"210_CR79","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/mus.20503","volume":"33","author":"MD Benson","year":"2006","unstructured":"Benson MD, Kluve-Beckerman B, Zeldenrust SR, et al. Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle Nerve. 2006;33:609\u201318.","journal-title":"Muscle Nerve"},{"key":"210_CR80","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","volume":"87","author":"RS Geary","year":"2015","unstructured":"Geary RS, Norris D, Yu R, Bennett CF. Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv Drug Deliv Rev. 2015;87:46\u201351.","journal-title":"Adv Drug Deliv Rev"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-020-00210-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-020-00210-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-020-00210-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T04:38:46Z","timestamp":1668832726000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-020-00210-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,18]]},"references-count":80,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["210"],"URL":"https:\/\/doi.org\/10.1007\/s40120-020-00210-7","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,18]]},"assertion":[{"value":"13 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}